Published in Physician Law Weekly, December 15th, 2004
In this new role, Hamm will oversee the company's legal responsibilities including corporate governance, U.S. Securities and Exchange Commission reporting, licensing, and merger and acquisition activity. Hamm will also serve as legal liaison with the appropriate agencies in facilitating the regulatory path forward for Dendreon's investigational lead product, Provenge, a targeted immunotherapy that is currently in a pivotal phase III clinical trial for the treatment of advanced prostate cancer.
Hamm has over 20 years' experience in various legal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.